X0206 3 2021-07-15 0 0001761918 Erasca, Inc. ERAS 0001283290 Lim Jonathan E C/O ERASCA, INC. 10835 ROAD TO THE CURE, SUITE 140 SAN DIEGO CA 92121 1 1 1 0 See Remarks 0001872346 Lim Conyee T. C/O ERASCA, INC. 10835 ROAD TO THE CURE, SUITE 140 SAN DIEGO CA 92121 0 0 1 0 0001872305 City Hill, LLC 4653 CARMEL MOUNTAIN ROAD, SUITE 308-501 SAN DIEGO CA 92121 0 0 1 0 Common Stock 15020832 I By Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005 Common Stock 6458333 I By City Hill, LLC Series A Preferred Stock 0.00 Common Stock 5135390 I By the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005 Series A Preferred Stock 0.00 Common Stock 5067694 I By City Hill, LLC Series B-1 Preferred Stock 0.00 Common Stock 280000 I By City Hill, LLC Series B-2 Preferred Stock 0.00 Common Stock 93333 I By City Hill, LLC Includes 1,644,532 shares subject to repurchase by us, which are subject to vesting. The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005. Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of such securities. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein. The shares of Series A Preferred Stock are convertible, at any time, at the holder's election, to shares of the Issuer's common stock at a ratio of 1.2-for-1. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A Preferred Stock will automatically convert to shares of the Issuer's common stock at a ratio of 1.2-for-1. The Series A Preferred Stock has no expiration date. The shares of Series B Preferred Stock are convertible, at any time, at the holder's election, to shares of the Issuer's common stock at a ratio of 1.2-for-1. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock will automatically convert to shares of the Issuer's common stock at a ratio of 1.2-for-1. The Series B Preferred Stock has no expiration date. Chairman and CEO Exhibit List: 24 - Power of Attorney /s/ Ebun S. Garner, Attorney-in-fact 2021-07-15